Tianyin to Attend Lazard Capital Markets 7th Annual Healthcare Conference on November 16 - 17, 2010

CHENGDU, China, Nov. 8, 2010 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals will attend Lazard Capital Markets 7th Annual Healthcare Conference from November 16 - 17, 2010 at the St. Regis Hotel in New York.

Dr. James Jiayuan Tong, Tianyin's Chief Financial Officer, Chief Business & Development Officer and Director is invited to present at 2:45 pm on November 17, at Fontainebleau of the St. Regis at 2 East 55th Street, New York, NY 10022.

An updated Company's presentation can be found on the Investors Relations of www.tianyinpharma.com

About Tianyin Pharmaceuticals

Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical medicine, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. Tianyin currently manufactures a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. Tianyin currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. Tianyin has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about Tianyin, please visit:  http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.